SAN FRANCISCO, Oct. 3, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it gained FDA market authorization for its Common Hereditary Cancers Panel. This ...
Allelica Collaborates with Invitae to Build Ancestry-Informed Polygenic Risk Score for Breast Cancer
Allelica and Invitae (NVTA) aim to decrease the gap in polygenic risk score (PRS) performance in individuals from diverse genetic ancestries, ensuring that the life-saving integration of genomic ...
Up to 5% of Americans may carry genetic variants associated with cancer risk, according to a cross-sectional analysis.The ...
A new editorial was published in Oncotarget's Volume 15 on December 24, 2024, titled "Pitfalls and perils from FDA-approved germ-line cancer predisposition tests." Authored by Dr. Wafik S. El-Deiry, ...
Publicly Funded Cancer Care: Are Adjuvant Therapies Prioritized Over Treatment of Metastatic Cancer? The Israeli Experience Patients with hereditary cancer syndromes face increased medical management ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback